AC Immune S.A.
(NQ:
ACIU
)
3.050
-0.010 (-0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about AC Immune S.A.
< Previous
1
2
Next >
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
April 05, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
March 20, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
March 16, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
March 08, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
February 07, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present at the SVB Securities Global Biopharma Conference
February 02, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
January 26, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
January 18, 2023
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
November 30, 2022
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
November 23, 2022
From
AC Immune SA
Via
GlobeNewswire
Is Ardelyx is A Buy After Slip in Early 2022
November 21, 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.